Investment13 Nov 2025, 12:45 pm
Lupin Establishes a New Global Standard in Sustainable Pharma with an S&P Global ESG Score of 91
AI Summary
Global pharma leader Lupin Limited has achieved an S&P Global ESG Score of 91 for 2025, significantly increasing from 17 in 2021 and surpassing the pharmaceutical industry average of 28. This remarkable increase ranks among the fastest for pharmaceutical companies, establishing Lupin as a leader in sustainable growth. Lupin has made significant progress across all three pillars - Environmental, Social, and Governance, including intensified environmental efforts, prioritizing employee well-being, and enhancing transparency and governance.
Key Highlights
- Lupin achieves an S&P Global ESG Score of 91, surpassing the pharmaceutical industry average of 28
- A 15-point increase from 2021, establishing Lupin as a leader in sustainable growth
- Significant progress in environmental efforts, social responsibility, and governance
- Increased use of renewable energy, reduced carbon emissions, and water-positive operations
- Prioritized employee well-being, launched community health programs, and societal healthcare contributions